SCHEMBL26817147

SCHEMBL26817147

Cn1nnnc1-c1ccc(Br)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.56
KMO O15229 1/20 0.52
ALDH1A1 P00352 4/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
LRRK2 Q5S007 2/20 0.43
CYP2C19 P33261 3/20 0.38
CYP1A2 P05177 3/20 0.38
CYP2C9 P11712 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ABCC9 O60706 1/20 0.37
ABCC8 Q09428 1/20 0.37
KCNJ11 Q14654 1/20 0.37
KCNJ8 Q15842 1/20 0.37
HSD11B1 P28845 1/20 0.37
P2RX7 Q99572 1/20 0.36
GAA P10253 1/20 0.35
ACLY P53396 1/20 0.35
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13838519 0.87 SMN1; SMN2 (0.56) SMN1; SMN2KMOALDH1A1LMNAMAPT
SCHEMBL6278071 0.81 SMN1; SMN2 (0.56) SMN1; SMN2KMOALDH1A1LMNAMAPT
SCHEMBL5063444 0.76 SMN1; SMN2 (0.50) SMN1; SMN2KMOALDH1A1LMNAMAPT
SCHEMBL5068065 0.76 SMN1; SMN2 (0.50) SMN1; SMN2KMOALDH1A1LMNAMAPT
SCHEMBL420682 0.75 SMN1; SMN2 (0.52) SMN1; SMN2KMOALDH1A1LMNACYP2C19
SCHEMBL8103794 0.75 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1MAPTLRRK2CYP2C19
SCHEMBL29037233 0.75 MKNK1 (0.50) SMN1; SMN2KMOALDH1A1LMNAMAPT
SCHEMBL25256533 0.74 SMN1; SMN2 (0.51) SMN1; SMN2KMOALDH1A1MAPTCYP2C19
SCHEMBL1092164 0.73 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1LMNAMAPTCYP2C19
SCHEMBL8785006 0.73 SMN1; SMN2 (0.43) SMN1; SMN2KMOALDH1A1LRRK2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357214-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357214-A1 NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY NR1H2, NR1H3, NR1H4 SMN1; SMN2 4853/4885KMO 1292/4885ALDH1A1 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.